CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB013

Allergen Testing

Defines BCBS Oklahoma reimbursement and coding stance for in-vitro allergen testing (specific IgE, total IgE, and other laboratory allergy tests) and when testing is reimbursable or not; applies to providers submitting claims to BCBS OK.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyAllergen Testing

Policy CodePolicy CPCPLAB013

Change TypeNo material changes

Effective DateNov 1, 2022

Next Review Date

Key ActionDocument in the medical record the indication and reason when in‑vitro specific IgE testing is used instead of skin testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

20maximum allergen-specific IgE tests reimbursable per year

specific IgEin‑vitro test reimbursable in lieu of skin testing

total IgEreimbursable for Xolair consideration or suspected ABPA

ALCATexplicitly not reimbursable

BATnot reimbursable

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for In‑Vitro Allergen Testing

When specific IgE in-vitro allergy testing is reimbursable

Covered when ANY of the following conditions are met:

In lieu of skin testing for initial screen: Specific IgE in-vitro testing may be reimbursable in lieu of skin testing for an INITIAL allergy screen when the medical record documents the indication and why it is being used instead of skin testing.

Medical record documentation required.

When skin testing contraindicated or results discordant: Reimbursable when skin testing is contraindicated (see Policy Guidelines) or when skin testing results are not consistent with the history of an anaphylactic or other severe reaction and confirmation would impact treatment decisions.

Contraindications include certain skin conditions, interfering medications, high-risk patients, recent anaphylaxis (within one month), or uncooperative patients.

Specific clinical indications: Reimbursable in the evaluation of individuals with asthma, suspected allergen-induced chronic rhinitis, suspected food allergy, suspected insect venom allergy, or suspected allergy to specific drugs.

Selection of allergens: Allergens chosen for testing must be based on the individual's history, physical examination, and environment.Maximum 20 allergen-specific antibodies per year

Total serum IgE: In-vitro testing for total serum IgE may be reimbursable for individuals with moderate to severe asthma being considered for omalizumab (Xolair) therapy or for individuals suspected of allergic bronchopulmonary aspergillosis (ABPA).

The policy explicitly identifies certain in‑vitro tests as not reimbursable. ALCAT (Antigen Leukocyte Antibody test) is not reimbursable. In‑vitro testing of allergen-specific IgG or non‑specific IgG, IgA, IgM, and/or IgD for evaluation of suspected allergy is not reimbursable. The policy also states that Basophil Activation flow cytometry testing (BAT) is not reimbursable, and that bead‑based epitope assays (for example, VeriMAP Peanut Dx) and non‑specific multi‑allergen qualitative IgE screens that do not identify specific allergens are not reimbursable.

The provided fragment does not list any additional, separate explicit exclusion criteria beyond the specific tests named as not reimbursable. References and citations are included in the document, but no further exclusion conditions are specified in this fragment.

The policy states that routine re‑testing for allergies to the same allergens is not reimbursable in the absence of a new clinical presentation. Reimbursement for repeat testing requires documentation of a new or changed clinical scenario that would justify repeat evaluation.

Beyond the specific not‑reimbursable tests and the routine re‑testing statement, the fragment does not define other conditions as explicitly "not medically necessary." No additional not‑medically‑necessary conditions are specified in this portion of the document.

Billing Codes and Test Limits

Listed laboratory/allergy testing codesmixed

82784
82785
82787
83516
83520
86001
86003
86005
86008
88184

1–10 of 13

1/2

Allergen-specific IgE test limit

Annual maximumLimited to 20 allergen-specific antibodies reimbursable per year

Selection requirementAllergens chosen for testing must be based on the individual's history, physical exam, and environment

Documentation noteTesting selection should be documented in the medical record to justify choices and limits

Provider Billing, Documentation, and Denial Risk

Billing Rule

Billing and code guidance

Follow applicable plan and coding requirements when billing listed laboratory and allergen testing codes. Providers are responsible for submission of accurate documentation and must submit claims using valid HIPAA-approved code sets per industry coding guidelines. Claims are subject to claim review and may be denied if documentation or coding is insufficient.

Affected codes include: 82784, 82785, 82787, 83516, 83520, 86001, 86003, 86005, 86008, 88184, 88185, 0165U, 0178U.

Prior Authorization

Prior authorization

Prior authorization requirements are not specified in this document fragment. Providers should verify product-specific prior authorization rules in the member’s plan documents or benefit portal before performing testing.

Background and Clinical Context

Allergen evaluation can be performed using either skin testing or in‑vitro specific IgE testing. The document notes that in‑vitro specific IgE testing may be reimbursable in lieu of skin testing for an initial allergy screen when the medical record documents the indication and why it is being used instead of skin testing. The policy also indicates that total serum IgE testing may be reimbursable when needed to evaluate candidates for omalizumab (Xolair) or when allergic bronchopulmonary aspergillosis (ABPA) is suspected. References included in the policy provide supporting clinical literature on atopic markers and testing variability that inform these recommendations.

Definitions and Clinical Terms

Contraindications to skin testing

Dermatographism and urticariaPatients with dermatographism or chronic urticaria are contraindicated for skin testing

Cutaneous mastocytosis and severe diffuse skin diseaseConditions such as cutaneous mastocytosis or severe diffuse psoriasis are contraindications to skin testing

Interfering medicationsUse of medications that interfere with anaphylaxis treatment (e.g., beta-blockers, ACE inhibitors) or reduce test sensitivity (e.g., tricyclics, antihistamines) contraindicates skin testing

High‑risk patients and recent anaphylaxisPoorly controlled asthma, recent anaphylactic event within one month, severe prior reactions, cardiac instability are contraindications

Uncooperative patientsUncooperative individuals (e.g., small children, those with mental or physical impairments) are contraindicated for skin testing